Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.47 |
| ▸ | PDE4A | P27815 | 2/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3934713 | 0.83 | GPR119 (0.55) | KDM1AGPR119BRD4PDE4BPDE4D | |
| SCHEMBL5201407 | 0.82 | IDO1 (0.54) | BCHEGPR119IDO1 | |
| SCHEMBL30393170 | 0.82 | IDO1 (0.54) | BCHEGPR119IDO1 | |
| SCHEMBL5454387 | 0.81 | GPR119 (0.57) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL19297086 | 0.81 | BRD4 (0.53) | KDM1AGPR119BRD4PDE4BPDE4D | |
| SCHEMBL19402410 | 0.78 | KDM1A (0.58) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL5205461 | 0.78 | IDO1 (0.48) | BCHEGPR119IDO1 | |
| SCHEMBL30885785 | 0.78 | IDO1 (0.48) | BCHEGPR119IDO1 | |
| SCHEMBL3805418 | 0.78 | KDM1A (0.53) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL21765007 | 0.77 | KDM1A (0.57) | KDM1AGPR119PDE4BPDE4DPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569638-B1 | AMINOALKOXYINDOLES AS 5-HT6-RECEPTOR LIGANDS FOR THE TREATMENT OF CNS-DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-7084169-B2 | Aminoalkoxyindoles and methods of use | ROCHE PALO ALTO LLC (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1569638-A1 | AMINOALKOXYINDOLES AS 5-HT6-RECEPTOR LIGANDS FOR THE TREATMENT OF CNS-DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-07 | — | — | EP | disclosed |
| US-20040132799-A1 | Aminoalkoxyindoles and methods of use | ROCHE PALO ALTO LLC (US) | 2004-07-08 | — | — | US | disclosed |
| WO-2004050085-A1 | AMINOALKOXYINDOLES AS 5-HT6-RECEPTOR LIGANDS FOR THE TREATMENT OF CNS-DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132799-A1 | Aminoalkoxyindoles and methods of use | HTR3C, HTR2C, CYP3A5 | KDM1A 929/4885BCHE 745/4885GPR119 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.